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Abstract
In metastatic colorectal cancer (CRC), actionable genetic lesions represent potential clinical opportunities. NTRK1, 2, and 
3 gene rearrangements encode oncogenic fusions of the tropomyosin-receptor kinase (TRK) family of receptor tyrosine 
kinases in different tumor types. The TPM3-NTRK1 rearrangement is a recurring event in CRC that renders tumors sensitive 
to TRKA kinase inhibitors in preclinical models. We identified abnormal expression of the TRKA protein in tumor and liver 
metastases of a CRC patient refractory to standard therapy. Molecular characterization unveiled a novel LMNA-NTRK1 
rearrangement within chromosome 1 with oncogenic potential, and the patient was treated with the pan-TRK inhibitor 
entrectinib, achieving partial response with decrease in hepatic target lesions from 6.8 and 8.2 cm in longest diameter to 4.7 
and 4.3 cm, respectively. To our knowledge, this is the first clinical evidence of efficacy for therapeutic inhibition of TRKA in 
a solid tumor, illuminating a genomic-driven strategy to identify CRCs reliant on this oncogene to be clinically targeted with 
entrectinib.
In a pan-cancer analysis of the transcriptomes of nearly 7000 
tumors from The Cancer Genome Atlas, it has been reported 
that NTRK1 (neurotrophic tyrosine kinase, receptor, type 1), 
NTRK2, and NTRK3 fusions occur across different tumors 
including CRC, indicating that such events represent a mecha-
nism of oncogenic activation for this family of receptor tyrosine 
kinases (1). We recently showed that the TPM3-NTRK1 rear-
rangement is a low-frequency (about 1%) recurring event in CRC, 
encoding a TPM3-TRKA–activated chimeric protein that ren-
ders tumors sensitive to tropomyosin receptor kinase A (TRKA 
kinase) inhibitors in preclinical models (2). We furthermore 
described an immunohistochemistry (IHC) approach to screen 
for tumors with rearranged TRKA, based on expression of its 
kinase domain. These studies provided the rationale for clinical 
investigation in CRC of the antitumoral activity of entrectinib 
(RXDX-101, NMS-E628), a novel, highly potent, and selective TRK, 
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ROS1 proto-oncogene receptor tyrosine kinase (ROS), and ana-
plastic lymphoma kinase (ALK) inhibitor (2–6).
A woman age 75 years with metastatic CRC progressing with-
out having had any objective response to previous therapies was 
referred to Niguarda Cancer Center for experimental targeted ther-
apies. The patient presented with Eastern Cooperative Oncology 
Group performance status 0, an intact primary colon tumor, peri-
toneal carcinomatosis and liver metastases, in hepatic segments 
6 and 5 of 6.8 and 8.2 cm in longest diameter, respectively, and 
right adrenal gland deposit of 2.2 cm. The primary tumor biop-
sied in August 2013 was colon adenocarcinoma (Figure 1A). The 
patient underwent molecular screening, performed ad hoc on a 
liver biopsy (March 2014), for which the patient provided informed 
consent and which displayed wild-type RAS and BRAF. We then 
tested for aberrancies of ALK, ROS1, and NTRK1 genes within the 
phase I, first-in-human study of entrectinib (EudraCT Number: 
2012-000148-88) and found by IHC that expression of TRKA protein 
was high in both the primary tumor as well as in liver metastasis 
(Figure 1B; Supplementary Figure 1, available online). However, the 
fluorescence-in situ hybridization (FISH) pattern (Figure 1C) was 
unexpectedly different from that observed for the TPM3 (exon 1–7)-
NTRK1 (exon 9–16) rearrangement previously reported to occur 
in CRC as the result of an intrachromosomal inversion within 
chromosome 1 (Supplementary Figure  2, available online) (2–7). 
The FISH pattern in this case rather suggested a deletion within 
Chromosome 1 involving the NTRK1 gene. We therefore investi-
gated this hypothesis, taking advantage of a patient-derived tumor 
xenograft generated from the liver biopsy in compliance with 
European and Italian Guidelines for Laboratory Animal Welfare, 
which mirrored histological, immunohistochemical, and FISH 
characteristics of the original tumor (Figure 1, D-F). Using a 5’RACE 
PCR approach, we unveiled a novel LMNA-NTRK1 gene rearrange-
ment, involving loss of the 5’ end of the NTRK1 gene, confirmed 
at genomic level by direct sequencing. Different proteins are pro-
duced by alternative splicing of the LMNA gene within exon 10–11, 
including Lamin A, Lamin C, and Progerin (8). Characterization by 
Sanger sequencing of the LMNA-NTRK1 rearrangement identified 
two distinct splice variant mRNAs, encoding exons 1–10 or 1–11 of 
the LMNA gene fused to exons 10–16 of the NTRK1 gene (Figure 2; 
Supplementary Figure 3, available online). Western blot analysis of 
tumor protein lysate with an antibody recognizing the C-terminus 
of TRKA revealed the presence of a doublet protein band at molec-
ular weights consistent with those predicted for the two splice 
variant chimeric proteins. As expected, the two bands were also 
recognized by anti-Lamin A/C antibody (Figure 2C). The degree of 
phosphorylation of the highly expressed fusion proteins indicates 
constitutive activation of TRKA kinase. The downstream transduc-
ers PLCγ1, AKT, and MAPK were also phosphorylated, similar to 
what was previously reported for TPM3-TRKA in the KM12 CRC 
cell line (Figure 2D) (2).
Based on these findings, the patient was treated with entrec-
tinib, starting in March 2014, with 1600 mg/m2 orally once daily for 
four consecutive days a week (ie, 4 days on/3 days off), for three con-
secutive weeks every 28 days. At a first response assessment, a CT 
scan in April 2014 (4 weeks after beginning entrectinib treatment) 
showed partial response, with shrinkage in sum of target lesions 
of 30%, which was confirmed by a CT scan performed four weeks 
later and maintained until July 2014. In particular, lesions in hepatic 
segments 6 and 5 decreased from 6.8 and 8.2 cm in longest diam-
eter to 4.7 and 4.3 cm, respectively (Supplementary Figure 4, avail-
able online); right adrenal gland metastases and peritoneal nodules 
also decreased in size (Supplementary Figure 5, available online).
Oncogenic fusions produced by translocations or other chro-
mosomal rearrangements have only infrequently been found 
in CRC (1). Here, we describe a novel LMNA-NTRK1 gene fusion 
in this disease. The LMNA gene has recently been identified 
(together with TP53) as involved in genomic alterations with 
NTRK1 occurring at relatively high frequency in Spitz nevi (10.7%), 
atypical Spitz tumors (25%), and Spitzoid melanoma (21.2%) (9). 
The LMNA-NTRK1 rearrangement reported here differs from that 
occurring in Spitzoid tumors and encompasses most of the LMNA 
gene fused to exon 10–16 of the NTRK1 gene, comprising an intact 
Figure 1. Histologic, immunohistochemical, and fluorescence in situ hybridization analyses of primary tumor and patient-derived xenograft from liver metastasis of 
the case presented. Hematoxylin and eosin, immunohistochemical and fluorescent in situ hybridization (FISH) images of primary tumor (A-C) and patient-derived 
xenograft from liver metastasis (D-F). In the immunohistochemical assays, NTRK1 antibody (TrkA Clone ID EP1058Y rabbit monoclonal antibody, EPITOMICS dil. 1:200) 
shows a strong cytoplasmic reactivity only in the neoplastic component (B, E). In the FISH analyses (C, F) the break-apart probe, which covers the NTRK1 locus (Sup-
plementary Figure 2, available online), shows presence of green signals (white arrows) only in absence of the red ones, suggesting a deletion of the NTRK1 gene. Mag-
nifications of images are 200X for (A, B, D, E) and 630X for (C and F).
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kinase domain. Alternative splicing at exon 10–11 of the LMNA 
gene, described in the literature as producing the splicing variants 
encoding Progerin and Lamin C, generates two different chimeric 
transcripts with NTRK1. LaminA/C are structural components 
of the nuclear lamina, a protein network underlying the inner 
nuclear membrane, which are highly expressed in colon tissue (8).
Figure 2. Identification of the new LMNA-NTRK1–activating rearrangement. A) Schematic representation of the LMNA-NTRK1 genomic DNA rearrangement and of the 
resulting transcripts. Introns are reported as lines, exons as colored boxes: LMNA in yellow, NTRK1 in green. The upper section shows in red the breakpoints leading to a 
deletion within chromosome 1 mapped to the genomic DNA (hg19 version), as identified by PCR/Sanger sequencing. Shown in the lower panel are the rearranged allele 
and the two identified alternative transcript variants, with or without the LMNA exon 11. B) Characterization of LMNA-NTRK1 transcripts by reverse transcription poly-
merase chain reaction (RT-PCR). The K562 control cell line, which expresses full-length NTRK1, shows expression of both NTRK1 extracellular and intracellular regions, 
while the tumor sample selectively expresses the intracellular region. PCR analysis of the region spanning the rearrangement shows the presence of two bands that, 
upon Sanger sequencing, correspond to two alternative splicing variants, with exons 1–10 or 1–11 of LMNA fused in frame to NTRK1 exon 10–16. LMNA expression was 
used as PCR control. C and D) Characterization of the tumor protein lysate sample by western blot. Analysis was performed with antibodies against C-terminus of TRKA 
(rabbit monoclonal, clone C17F1, 1:1000 dilution, cell signaling) or against Lamin A/C (mouse monoclonal, clone 4C11, 1:2000 dilution, cell signaling). KM12 xenograft 
lysate was used as a reference (C). Phosphorylation of LMNA-TRKA and its downstream targets PLCγ1, AKT, and MAPK was analyzed using the following antibodies: 
phospho-TRKA-Tyr490 (rabbit polyclonal, 1:500 dilution, Calbiochem), Phospho-PLCγ1-Tyr783, PLCγ1, AKT, Phospho-MAPK-Thr202/Tyr204, MAPK (rabbit polyclonals, 
1:1000 dilution, cell signaling), Phospho AKT Ser473 (rabbit monoclonal, clone D9E, 1:1000 dilution, cell signaling). GAPDH (rabbit polyclonal 1:2500 dilution, Santacruz) 
is reported for normalization purposes (D). TRK = tropomyosin-receptor kinase; WT = wild-type.
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The limitation of the present study resides in reporting a 
single case. However, the rarity of occurrence of fusion genes 
in CRC precludes clinical studies in large series. The latter will 
be possible only if pharmaceutical interest and rationale will 
be triggered by knowledge of successful uncommon cases such 
as the present one. Furthermore, if applied routinely a screen-
ing based on NTRK assessment by immunohistochemistry 
followed by targeted NGS based on anchored multiplex polyer-
mase chain reaction (10) will enhance identification of patients 
who can benefit from entrectinib treatment in CRC and other 
histologies.
Entrectinib is a selective pan-TRK, ROS1, and ALK kinase 
inhibitor with strong preclinical activity in multiple cancer 
models where these targets are constitutively activated (2–4) 
and which is currently being developed in phase I  clinical 
studies for tumors with TRK, ROS, or ALK gene aberrations 
(6). While clinical responses to ALK and ROS inhibitors have 
already been observed in lung tumor patients treated with 
crizotinib, ceritinib, alectinib, and other drugs in devel-
opment, including entrectinib, clinical responses to TRK 
inhibition have never, to our knowledge, previously been doc-
umented. The landscape of therapeutically actionable molec-
ular alterations in CRC appears to be increasingly populated 
by myriad gene abnormalities, among which NTRK gene rear-
rangements encoding novel oncogenic fusions (2,11,12) are 
promising targets to be captured by rapidly evolving tech-
nologies (10).
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